Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

7 trials 2 recruiting Orphan designation

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

5 Completed trials

1 Sponsors

18 Countries

Phase III

Phase II

Phase III: 6 Phase II: 1

Sponsors using this IMP

Arrowhead Pharmaceuticals Inc. 7

All trials

7 total

Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting

2024-519712-13-00 Phase III 14 countries Arrowhead Pharmaceuticals Inc.
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia at high risk of Acute Pancreatitis (SHASTA-5 Study) Recruiting

2024-518206-40-00 Phase III 5 countries Arrowhead Pharmaceuticals Inc.
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended

2023-509301-80-00 Phase III 10 countries Arrowhead Pharmaceuticals Inc.
Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended

2023-509302-30-00 Phase III 9 countries Arrowhead Pharmaceuticals Inc.
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Phase III 10 countries Arrowhead Pharmaceuticals Inc.
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia Ended

2024-511331-96-00 Phase II 3 countries Arrowhead Pharmaceuticals Inc.
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome Ended

2024-514336-24-00 Phase III 7 countries Arrowhead Pharmaceuticals Inc.

Showing 1–7 of 7 trials

← All drugs A–Z